<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1071">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05147207</url>
  </required_header>
  <id_info>
    <org_study_id>SURG-387-17</org_study_id>
    <nct_id>NCT05147207</nct_id>
  </id_info>
  <brief_title>SuperPath Versus Posterior Approach for THA</brief_title>
  <official_title>Supercapsular Percutaneously-Assisted Total Hip (SuperPATHÂ®) Versus Conventional Posterior Approach for Total Hip Arthroplasty: A Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Queen's University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The SuperPATH approach is a minimally invasive approach for total hip arthroplasty. This&#xD;
      project randomized patients to the SuperPath versus posterior approach. Outcomes examined&#xD;
      included functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic&#xD;
      component positions. Participants were followed for 2 years. The aim was to examine if the&#xD;
      SuperPATH approach provided significant advantages over the posterior approach on functional&#xD;
      testing or return to work for patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: The Supercapsular Percutaneously-Assisted Total Hip (SuperPATH) approach is a&#xD;
      minimally invasive approach for total hip arthroplasty. It has been reported to show earlier&#xD;
      mobilization, better gait kinematics, and short hospital length of stay. Our primary&#xD;
      objective was to compare functional tests of timed up and go and timed stair climb&#xD;
      preoperatively, at discharge, 2 weeks, and 6 weeks postoperatively. Secondary objectives&#xD;
      included the return to function in weeks, Oxford hip scores, visual analog scale, narcotic&#xD;
      utilization, perioperative outcomes, and radiographic component positions.&#xD;
&#xD;
      Methods: Forty-six patients were randomized into two groups on the surgery day: the SuperPATH&#xD;
      group (25 patients) and the Posterior group (20 patients). Outcomes examined included&#xD;
      functional, VAS pain, narcotic utilization, perioperative outcomes, and radiographic&#xD;
      component positions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2017</start_date>
  <completion_date type="Actual">June 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>superpath approach versus posterior approach</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>function</measure>
    <time_frame>24 months</time_frame>
    <description>TUG test</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Surgical Approach</condition>
  <condition>Hip Arthropathy</condition>
  <arm_group>
    <arm_group_label>Superpath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a minimally invasive surgical approach.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Posterior Approach</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This is the traditional THA surgical approach used.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Superpath Approach</intervention_name>
    <description>This is a minimally invasive surgical approach for THA.</description>
    <arm_group_label>Superpath</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Non-inflammatory degenerative joint disease including osteoarthritis, traumatic&#xD;
             arthritis, or avascular necrosis;&#xD;
&#xD;
          -  Inflammatory degenerative joint disease including rheumatoid arthritis;&#xD;
&#xD;
          -  Correction of functional deformity.&#xD;
&#xD;
          -  Subject is skeletally mature (21 years of age or older);&#xD;
&#xD;
          -  Subject is a candidate to be implanted with the specified combination of components;&#xD;
&#xD;
          -  Subject is willing and able to complete required study visits and assessments;&#xD;
&#xD;
          -  Subject plans to be available through the follow-up visits;&#xD;
&#xD;
          -  Subject is willing to sign the approved informed consent document.&#xD;
&#xD;
          -  Subjects with a previous THA in the contralateral hip are eligible for enrollment&#xD;
             provided it has been at least 1 year since the contralateral THA and the contralateral&#xD;
             THA is asymptomatic and not pending revision. Simultaneous bilateral THA subjects will&#xD;
             not be permitted to enroll.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has overt infection or distant foci of infections;&#xD;
&#xD;
          -  Subject has rapid disease progression as manifested by joint destruction or bone&#xD;
             absorption apparent on roentgenogram;&#xD;
&#xD;
          -  Subject with inadequate neuromuscular status (e.g. prior paralysis, fusion and/or&#xD;
             inadequate abductor strength), poor bone stock, poor skin coverage around the joint&#xD;
             which would make the procedure unjustifiable;&#xD;
&#xD;
          -  Subject has a neuropathic joints;&#xD;
&#xD;
          -  Subject has hepatitis or HIV infection;&#xD;
&#xD;
          -  Subject has a neurological or musculoskeletal disease that may adversely affect gait&#xD;
             or weight-bearing;&#xD;
&#xD;
          -  Subject is currently enrolled in another clinical investigation that could affect the&#xD;
             endpoints of this study;&#xD;
&#xD;
          -  Subject is unwilling or unable to sign the informed consent document;&#xD;
&#xD;
          -  Subject has documented substance abuse issues;&#xD;
&#xD;
          -  Subject has a body mass index (BMI) of greater than 40;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kingston General Hospital</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen's University</investigator_affiliation>
    <investigator_full_name>Dr. Gavin Wood</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Joint Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

